Europe T Cell Therapy Market Forecast to 2030

According to the research team’ research, the Europe T cell therapy market was valued at US$ 699.24 million in 2022 and is expected to reach US$ 2,345.49 million by 2030, registering a CAGR of 16.3% from 2022 to 2030. Growing burden of cancer worldwide and increasing number of approvals of t-cell therapies are among the critical factors attributed to the Europe T cell therapy market expansion.

Globally, companies operating in the T-cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few noteworthy developments in the T-cell therapy market are mentioned below.

In August 2023, Astellas invested US$ 50 million in Poseida’s CAR T-cell therapy. Astellas will have exclusive negotiation and first refusal for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement. P-MUC1C-ALLO1 is an allogeneic CAR T-cell therapy targeting cancer-specific Mucin 1 protein (MUC1-C) forms. It is currently under investigation in an open-label multicentre Phase I clinical trial (NCT05239143) treating multiple epithelial-derived solid tumor indications. In May 2023, Laurus Labs’ stake in ImmunoACT will now increase to 33.86% on a fully diluted basis post completion of the deal. The company had already acquired 26.62% of stakes in ImmunoACT in November 2021. ImmunoACT has a portfolio of CAR T-cell therapy assets under various development stages for treating multiple autoimmune diseases and oncology indications. This investment further strengthens Laurus Labs’ commitment to accessing novel Cell and Gene Therapy technology and enhances its affordability for patients. This investment will further help ImmunoACT to gear up for the manufacture of more treatments. In November 2021, Autolus Therapeutics plc (a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies) and Blackstone Life Sciences entered into a strategic collaboration and financing agreement under which funds managed by Blackstone will provide up to US$ 250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as the next-generation product therapies of obe-cel in B-cell malignancies. Thus, these investments create lucrative opportunities in the Europe T-cell therapy market.

On the contrary, side-effects of CAR T-cell therapy hampers on the growth of Europe T cell therapy market.

Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 89.8% market share in 2022, amassing US$ 628.03 million. It is projected to garner US$ 2,153.22 million by 2030 to expand at 16.7% CAGR during 2022-2030.

Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 95.3% share of Europe T cell therapy market in 2022, amassing US$ 666.04 million. It is projected to garner US$ 2,275.14 million by 2030 to expand at 16.6% CAGR during 2022-2030.

Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 95.3% share of Europe T cell therapy market in 2022, amassing US$ 666.04 million. It is projected to garner US$ 2,275.14 million by 2030 to expand at 16.6% CAGR during 2022-2030.

Based on country, the Europe T cell therapy market has been categorized into Germany, UK, France, Italy, Spain, the Rest of Europe. Our regional analysis states that Germany captured 31.0% share of Europe T cell therapy market in 2022. It was assessed at US$ 216.92 million in 2022 and is likely to hit US$ 773.96 million by 2030, exhibiting a CAGR of 17.2% during 2022-2030.

Key players operating in the Europe T cell therapy market are Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG, among others.

May 2022: Legend Biotech Corporation announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies.

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Europe T Cell Therapy Market, by Country (US$ Million)
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe T Cell Therapy Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Growing Burden of Cancer Worldwide
4.1.2 Increasing Number of T-Cell Therapy Approvals
4.2 Market Restraints
4.2.1 Side-effects of CAR T-Cell Therapy
4.3 Market Opportunities
4.3.1 Growing Investment in T-Cell Therapy
4.4 Future Trends
4.4.1 Rising Number of CAR T-Cell Therapies in Clinical Trials
4.5 Impact Analysis:
5. T Cell Therapy Market – Europe Market Analysis
5.1 Europe T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
6. Europe T Cell Therapy Market – Revenue and Forecast to 2030 – by Modality.
6.1 Overview
6.2 Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
6.3 Research
6.3.1 Overview
6.3.2 Research: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Commercialized
6.4.1 Overview
6.4.2 Commercialized: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe T Cell Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
7.3 CAR T-cell Therapy
7.3.1 Overview
7.3.2 CAR T-cell Therapy: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 T-cell Receptor (TCR)-based.
7.4.1 Overview
7.4.2 T-cell Receptor (TCR)-based: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8. Europe T Cell Therapy Market – Revenue and Forecast to 2030 – by Indication
8.1 Overview
8.2 Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Hematologic Malignancies
8.3.1 Overview
8.3.2 Hematologic Malignancies: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.3.3 Europe T Cell Therapy Market, by Haematological Malignancies, 2020-2030 (US$ Million)
8.4 Solid Tumor
8.4.1 Overview
8.4.2 Solid Tumor: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Europe T Cell Therapy Market – Country Analysis
9.1 Europe
9.1.1.1 Europe T Cell Therapy Market, by Country
9.1.1.2 UK
9.1.1.2.1 UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.2.2 UK: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.2.3 UK: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.2.4 UK: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.2.4.1 UK: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.3 Germany
9.1.1.3.1 Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.3.2 Germany: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.3.3 Germany: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.3.4 Germany: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.3.4.1 Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.4 France
9.1.1.4.1 France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.4.2 France: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.4.3 France: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.4.4 France: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.4.4.1 France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.5 Italy
9.1.1.5.1 Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.5.2 Italy: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.5.3 Italy: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.5.4 Italy: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.5.4.1 Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.6 Spain
9.1.1.6.1 Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.6.2 Spain: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.6.3 Spain: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.6.4 Spain: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.6.4.1 Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
9.1.1.7 Rest of Europe
9.1.1.7.1 Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
9.1.1.7.2 Rest of Europe: Europe T Cell Therapy Market, by Modality, 2020-2030 (US$ Million)
9.1.1.7.3 Rest of Europe: Europe T Cell Therapy Market, by Therapy Type, 2020-2030 (US$ Million)
9.1.1.7.4 Rest of Europe: Europe T Cell Therapy Market, by Indication, 2020-2030 (US$ Million)
9.1.1.7.4.1 Rest of Europe: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication, 2020-2030 (US$ Million)
10. T Cell Therapy Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in T Cell Therapy Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Immunocore Holdings Plc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Legend Biotech Corp
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Janssen Global Services LLC
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Gilead Sciences Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Bristol-Myers Squibb Co
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Novartis AG
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Innovent Biologics Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms

Table 1. Europe T Cell Therapy Market Segmentation
Table 2. Europe T Cell Therapy Market, by Hematological Malignancies – Revenue and Forecast to 2030 (US$ Million)
Table 3. UK Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany: Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany: Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany: Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 11. France: Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 12. France: Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. France: Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 14. France: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy: Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy: Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 17. Italy: Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 18. Italy: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain: Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain: Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 21. Spain: Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Spain: Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe T Cell Therapy Market, by Modality – Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe T Cell Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 25. Rest of Europe T Cell Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 26. Rest of Europe T Cell Therapy Market, For Hematologic Malignancies by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 27. Recent Organic Growth Strategies in Europe T Cell Therapy Market
Table 28. Recent Inorganic Growth Strategies in the Europe T Cell Therapy Market
Table 29. Glossary of Terms, Europe T Cell Therapy Market

Figure 1. Europe T Cell Therapy Market Segmentation, By Country
Figure 2. Europe T Cell Therapy Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe T Cell Therapy Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Europe T Cell Therapy Market Revenue Share, by Modality, 2022 & 2030 (%)
Figure 6. Research: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Commercialized: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Europe T Cell Therapy Market Revenue Share, by Therapy Type 2022 & 2030 (%)
Figure 9. CAR T-cell Therapy: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. T-cell Receptor (TCR)-based: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Europe T Cell Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 12. Hematologic Malignancies: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Solid Tumor: Europe T Cell Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe T Cell Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 15. Europe T Cell Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 16. UK Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. Germany: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. France: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Italy: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Spain: Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Rest of Europe T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Growth Strategies in T Cell Therapy Market